Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women | Breast Cancer | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Rossouw JE, Anderson GL, Prentice RL,  et al; Writing Group for the Women's Health Initiative Investigators.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;288(3):321-33312117397PubMedGoogle ScholarCrossref
Chlebowski RT, Hendrix SL, Langer RD,  et al; WHI Investigators.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial.  JAMA. 2003;289(24):3243-325312824205PubMedGoogle ScholarCrossref
Chlebowski RT, Anderson GL, Pettinger M,  et al; Women's Health Initiative Investigators.  Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.  Arch Intern Med. 2008;168(4):370-37718299491PubMedGoogle ScholarCrossref
Chlebowski RT, Kuller LH, Prentice RL,  et al; WHI Investigators.  Breast cancer after use of estrogen plus progestin in postmenopausal women.  N Engl J Med. 2009;360(6):573-58719196674PubMedGoogle ScholarCrossref
Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.  J Clin Oncol. 1998;16(9):3115-31209738583PubMedGoogle Scholar
Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.  Cancer. 2004;101(7):1490-150015378477PubMedGoogle ScholarCrossref
Rosenberg LU, Granath F, Dickman PW,  et al.  Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study.  Breast Cancer Res. 2008;10(5):R7818803850PubMedGoogle ScholarCrossref
Beral V.Million Women Study Collaborators.  Breast cancer and hormone-replacement therapy in the Million Women Study.  Lancet. 2003;362(9382):419-42712927427PubMedGoogle ScholarCrossref
Kerlikowske K, Miglioretti DL, Ballard-Barbash R,  et al.  Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.  J Clin Oncol. 2003;21(23):4314-432114645420PubMedGoogle ScholarCrossref
Newcomb PA, Egan KM, Trentham-Dietz A,  et al.  Prediagnostic use of hormone therapy and mortality after breast cancer.  Cancer Epidemiol Biomarkers Prev. 2008;17(4):864-87118381475PubMedGoogle ScholarCrossref
Christante D, Pommier S, Garreau J, Muller P, LaFleur B, Pommier R. Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up.  Am J Surg. 2008;196(4):505-51118809052PubMedGoogle ScholarCrossref
Women's Health Initiative Study Group.  Design of the Women's Health Initiative clinical trial and observational study.  Control Clin Trials. 1998;19(1):61-1099492970PubMedGoogle ScholarCrossref
Hays J, Hunt JR, Hubbell FA,  et al.  The Women's Health Initiative recruitment methods and results.  Ann Epidemiol. 2003;13(9):(suppl)  S18-S7714575939PubMedGoogle ScholarCrossref
Anderson GL, Manson J, Wallace R,  et al.  Implementation of the Women's Health Initiative study design.  Ann Epidemiol. 2003;13(9):(suppl)  S5-S1714575938PubMedGoogle ScholarCrossref
Rossouw JE, Prentice RL, Manson JE,  et al.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.  JAMA. 2007;297(13):1465-147717405972PubMedGoogle ScholarCrossref
Curb JD, McTiernan A, Heckbert SR,  et al; WHI Morbidity and Mortality Committee.  Outcomes ascertainment and adjudication methods in the Women's Health Initiative.  Ann Epidemiol. 2003;13(9):(suppl)  S122-S12814575944PubMedGoogle ScholarCrossref
National Cancer Institute.  Surveillance, Epidemiology, and End Results program. Accessed September 24, 2009
Sener SF, Winchester DJ, Winchester DP,  et al.  The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival.  Am J Surg. 2009;197(3):403-40719245923PubMedGoogle ScholarCrossref
Heiss G, Wallace R, Anderson GL,  et al; WHI Investigators.  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.  JAMA. 2008;299(9):1036-104518319414PubMedGoogle ScholarCrossref
Joffe MM, Byrne C, Colditz GA. Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias.  Epidemiology. 2001;12(4):429-43811416781PubMedGoogle ScholarCrossref
Shen Y, Yang Y, Inoue LYT, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.  J Natl Cancer Inst. 2005;97(16):1195-120316106024PubMedGoogle ScholarCrossref
Sihto H, Lundin J, Lehtimäki T,  et al.  Molecular subtypes of breast cancers detected in mammography screening and outside of screening.  Clin Cancer Res. 2008;14(13):4103-411018593987PubMedGoogle ScholarCrossref
Dong W, Berry DA, Bevers TB,  et al.  Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the University of Texas M. D. Anderson Cancer Center experience.  Cancer Epidemiol Biomarkers Prev. 2008;17(5):1096-110318483331PubMedGoogle ScholarCrossref
Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence.  J Clin Oncol. 2006;24(33):e49-e5017114650PubMedGoogle ScholarCrossref
Ravdin PM, Cronin KA, Howlader N,  et al.  The decrease in breast-cancer incidence in 2003 in the United States.  N Engl J Med. 2007;356(16):1670-167417442911PubMedGoogle ScholarCrossref
Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence.  JAMA. 2004;291(1):47-5314709575PubMedGoogle ScholarCrossref
Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.  J Clin Oncol. 2007;25(25):3808-381517664460PubMedGoogle ScholarCrossref
Chlebowski RT, Schwartz AG, Wakelee H,  et al; Women's Health Initiative Investigators.  Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.  Lancet. 2009;374(9697):1243-125119767090PubMedGoogle ScholarCrossref
Losordo DW, Isner JM. Estrogen and angiogenesis: a review.  Arterioscler Thromb Vasc Biol. 2001;21(1):6-1211145928PubMedGoogle ScholarCrossref
Dobrzycka B, Kinalski M, Piechocka D, Terlikowski SJ. The role of estrogens in angiogenesis in the female reproductive system [in Polish].  Endokrynol Pol. 2009;60(3):210-21419569022PubMedGoogle Scholar
Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.  Cancer Res. 2007;67(20):9929-993617942925PubMedGoogle ScholarCrossref
Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells.  Cancer Res. 1998;58(3):392-3959458078PubMedGoogle Scholar
Calvo A, Catena R, Noble MS,  et al.  Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis.  Oncogene. 2008;27(40):5373-538418504437PubMedGoogle ScholarCrossref
Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma.  N Engl J Med. 1991;324(1):1-81701519PubMedGoogle ScholarCrossref
Power ML, Anderson BL, Schulkin J. Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical.  Menopause. 2009;16(3):500-50819169162PubMedGoogle ScholarCrossref
Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT.  Atherosclerosis. 2009;207(2):336-34019560146PubMedGoogle ScholarCrossref
Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? a randomized trial.  Ann Intern Med. 2010;152(4):211-21720157135PubMedGoogle ScholarCrossref
Prentice RL, Chlebowski RT, Stefanick ML,  et al.  Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.  Am J Epidemiol. 2008;167(10):1207-121618372396PubMedGoogle ScholarCrossref
Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?  J Clin Oncol. 2009;27(31):5138-514319752341PubMedGoogle ScholarCrossref
Anderson GL, Chlebowski RT, Rossouw JE,  et al.  Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.  Maturitas. 2006;55(2):103-11516815651PubMedGoogle ScholarCrossref
Original Contribution
Clinician's Corner
October 20, 2010

Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women

Author Affiliations

Author Affiliations: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California (Dr Chlebowski); Fred Hutchinson Cancer Research Center, Seattle, Washington (Drs Anderson and Prentice and Mr Aragaki); University of Cincinnati, Cincinnati, Ohio (Dr Gass); State University of New York at Stony Brook (Dr Lane); University of Pittsburgh, Pittsburgh, Pennsylvania (Dr Kuller); Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Manson); Stanford Prevention Research Center, Stanford, California (Dr Stefanick); University of Massachusetts/ Fallon Clinic, Worcester (Dr Ockene); University of Wisconsin, Madison (Dr Sarto); University of Tennessee Health Science Center, Memphis (Dr Johnson); University at Buffalo, Buffalo, New York (Dr Wactawski-Wende); Cancer Therapy and Research Center (Dr Ravdin) and University of Texas Health Science Center (Dr Schenken), San Antonio; Wayne State School of Medicine and Hurtzel Hosptial, Detroit, Michigan (Dr Hendrix); Baylor College of Medicine, Houston, Texas (Dr Rajkovic); Albert Einstein College of Medicine, New York, New York (Dr Rohan); and University of California at Davis, Sacramento (Dr Yasmeen).

JAMA. 2010;304(15):1684-1692. doi:10.1001/jama.2010.1500

Context In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported.

Objective To determine the effects of therapy with estrogen plus progestin on cumulative breast cancer incidence and mortality after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009.

Design, Setting, and Participants A total of 16 608 postmenopausal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill. After the original trial completion date (March 31, 2005), reconsent was required for continued follow-up for breast cancer incidence and was obtained from 12 788 (83%) of the surviving participants.

Main Outcome Measures Invasive breast cancer incidence and breast cancer mortality.

Results In intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up on March 31, 2005, estrogen plus progestin was associated with more invasive breast cancers compared with placebo (385 cases [0.42% per year] vs 293 cases [0.34% per year]; hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.07-1.46; P = .004). Breast cancers in the estrogen-plus-progestin group were similar in histology and grade to breast cancers in the placebo group but were more likely to be node-positive (81 [23.7%] vs 43 [16.2%], respectively; HR, 1.78; 95% CI, 1.23-2.58; P = .03). There were more deaths directly attributed to breast cancer (25 deaths [0.03% per year] vs 12 deaths [0.01% per year]; HR, 1.96; 95% CI, 1.00-4.04; P = .049) as well as more deaths from all causes occurring after a breast cancer diagnosis (51 deaths [0.05% per year] vs 31 deaths [0.03% per year]; HR, 1.57; 95% CI, 1.01-2.48; P = .045) among women who received estrogen plus progestin compared with women in the placebo group.

Conclusions Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive. Breast cancer mortality also appears to be increased with combined use of estrogen plus progestin.

Trial Registration Identifier: NCT00000611